An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial

By the PROTEKT Study Group   Massicotte P.   Julian J.A.   Gent M.   Shields K.   Marzinotto V.   Szechtman B.   Chan A.K.   Andrew M.  

Thrombosis Research, Vol. 109, Iss. 2, 2003-01 ,pp. : 101-108

Elsevier

Access to resources Recommend Favorite

Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: A prospective randomized placebo-controlled trial

By Qublan H.   Amarin Z.   Dabbas M.   Farraj A. -E.   Beni-Merei Z.   Al-Akash H.   Bdoor A. -N.   Nawasreh M.   Malkawi S.   Diab F.   Al-Ahmad N.   Balawneh M.   Abu-Salim A.  

Human Fertility, Vol. 11, Iss. 4, 2008-12 ,pp. : 246-253

Informa Healthcare

Access to resources Recommend Favorite

Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial

By Urman B.   Ata B.   Yakin K.   Alatas C.   Aksoy S.   Mercan R.   Balaban B.  

Human Reproduction, Vol. 24, Iss. 7, 2009-07 ,pp. : 1640-1647

Oxford University Press

Access to resources Recommend Favorite

For the Initial Treatment of Venous Thromboembolism - Are All Low-molecular-weight Heparin Compounds the Same?

By van der Heijden J.F.   Prins M.H.   Buller H.R.  

Thrombosis Research, Vol. 100, Iss. 2, 2000-10 ,pp. : 121-130

Elsevier

Access to resources Recommend Favorite

Prevention of Venous Thromboembolism - Prophylaxis with a low molecular weight heparin (Fragmin)

By Agnelli G.   Sonaglia F.  

Thrombosis Research, Vol. 97, Iss. 1, 2000-01 ,pp. : 49-62

Elsevier

Access to resources Recommend Favorite